Although the lung is an obvious target for site-specific delivery of many therapeutics for respiratory 36 airway diseases such as asthma, COPD, and cystic fibrosis, novel strategies are needed to avoid key 37 physiologic barriers for efficient delivery and controlled release of therapeutics to the lungs. Specifically, 38 deposition into the deep lung requires particles with a 1-5 µm aerodynamic diameter; however, particles 39 with a geometric diameter less than 6 µm are rapidly cleared by alveolar macrophages. Additionally, 40 epithelial, endothelial, and fibroblast cells prefer smaller (< 300 nm) nanoparticles for efficient 41 endocytosis. Here we address these contradictory design requirements by using a nanoparticle-inside-42 microgel system (Nano-in-Microgel). Using an improved maleimide-thiol based Michael Addition during 43 (water-in-oil) Emulsion (MADE) method, we fabricated both trypsin-responsive and neutrophil elastase-44 responsive polymeric Nano-in-Microgel to show the versatility of the system in easily exchanging 45 enzyme-responsive crosslinkers for disease-specific proteases. By varying the initial macromer 46 concentration, from 20-50 % w/v, the size distribution means ranged from 4-8 µm, enzymatic 47 degradation of the microgels is within 30 minutes, and in vitro macrophage phagocytosis is lower for the 48 higher % w/v. We further demonstrated that in vivo lung delivery of the multi-stage carriers through the 49 pulmonary route yields particle retention up to several hours and followed by clearance within in naïve 50 mice. Our results provide a further understanding of how enzymatically-degradable multi-stage 51 polymeric carriers can be used for pulmonary drug delivery. 52 53
Macrophage Uptake Study: RAW 264.7 Macrophage cells (ATCC, Manassas, USA) were cultured in 164 DMEM medium supplemented with 10% Fetal Bovine Serum (FBS) 100 U/mL/100 µg/mL Penicillin-165 Streptomycin (HyClone, Logan, USA) in a 37ºC incubator with 5% CO2. RAW cells were detached by 166 scraping and stained with CellTrace Yellow (ThermoFisher) following manufacturer instructions, then 167 incubated with 20-50% w/v Nano-in-Microgel at a 1:1 ratio in a 96 well V-bottom plate. At 0.5, 1, 2, 6, 168 and 12 hours the plates were moved to 4ºC, and the cells stained with Zombie Green (BioLegend, San 169 Diego, USA) and fixed with Cytofix (BD Biosciences, San Jose, USA). Fluorescence was evaluated 170 using a BD LSRFortessa with a high-throughput system. 171 172 Pulmonary Administration and whole organ imaging: All studies were performed according to 173 protocols approved by the IACUC at the Georgia Institute of Technology and all methods were 174 performed in accordance with the relevant guidelines and regulations. C57BL/6 and 8-12 weeks old 175 female Balb/c mice (Jackson Laboratories, Bar Harbor, USA) were maintained in pathogen-free 176 facilities, given sterile water, and food (low alfalfa if used for imaging) ad libitum. Using a 1A-1C 177
MicroSprayer Aerosolizer and FMJ-250 high pressure syringe assembly (Penn-Century, Inc) for 178 aerosolized delivery, mice were anesthetized with a Ketamine/Xylazine 80-100 mg/kg/ 10-20 mg/kg 179 cocktail, positioned on an intubation table, endotracheally intubated with a 1.22 mm ET Tube (Hallowell 180 EMC, Pittsfield, USA), and swollen Nano-in-Microgel formulations (1e6 microgels in 50 µL) were 181 injected. If there was injection failure, the mouse was marked for follow up and removed from data sets; 182 all samples removed are marked within the relevant supplemental figures. For oropharyngeal 183 aspirations, mice were anesthetized with isoflurane, placed on an intubation table, then the tongue was 184 pulled and held with atraumatic forceps as the formulation was administered into the mouth, and the 185 nose gently covered until the liquid was inhaled. Within experiments, the concentration of microgels 186 was equal between formulations. After sacrificing the mice with sodium pentobarbital, perfusing the 187 lungs with PBS through the right ventricle then excising the lungs, the fluorescence intensity of the 188 particles. This range is represented by dashed red lines on Figure 2B and suggests that the design 253 criteria for optimal aerodynamic diameter for deep lung delivery is met. In the future, the actual 254 aerodynamic diameter measured by a next generation impactor, after developing a dry powder 255 formulation, would be necessary to account for microgel aggregation, density, and shape factor. 256 criteria for proteolytic degradation of the microgels by the incorporated peptide backbone, Nano-in-272
synthesis and degradation process for the Nano-in-Microgel formulation. To fabricate the Nano-in-232

Microgels, a Michael Addition reaction During water-in-oil Emulsion (MADE) was used. 4-arm PEG 233
Maleimide and DyLight 650 4-arm PEG Mal is crosslinked by a protease-responsive di-thiol peptide in
Microgels were loaded into microfluidic, PDMS single cell traps [32] then exposed to the relevant 273 proteases and imaged over time ( Figure 3A) . Trypsin-responsive microgels were exposed to 0.01 274 mg/mL of trypsin (≥ 90 u/mL). For all formulations, 95% of the microgels degraded within 20 minutes. 275
These studies were repeated with the elastase-responsive microgels, which were exposed to pooled 276 sputum from cystic fibrosis patients (courtesy of the Emory Cystic Fibrosis Center, Atlanta, GA). For all 277 elastase-responsive microgel formulations, 95% of the microgels degraded within 25 minutes of 278 exposure to the sputum. It is possible that the protease-responsive crosslinkers in these microgels 279 could non-specifically degraded by other proteases present in the disease state; e.g., matriptase for the 280 trypsin-responsive peptide or cathepsin S for the elastase-responsive peptide (identified using 281
PACMANs[34]), and this in vivo degradation rate in disease states could be faster -an aspect we plan 282 to evaluate in future studies. Non-enzyme degradable 20% w/v microgels were fabricated by 283 crosslinking with a dithiol PEG and exposed to 0.01 mg/mL of trypsin (≥ 900 u/mL) as a control to show 284 the peptide crosslinker is necessary for enzyme-responsive degradation. The fluorescence change of 285 the non-enzymatically degradable PEG microgels followed similar trend as several sets of trypsin and 286 elastase crosslinked microgels that were imaged without exposure to the enzyme to confirm limited 287 bleaching of the microgels; the mean at 25 minutes is 91%, Figure 3B -indicating minimal background 288 degradation. 289 290 Interestingly, we did not observe a difference in degradation when varying polymer concentrations. This 291 could be due to either the limits of the measurement method (1-minute intervals) or the polydispersity of 292 the microgels and overlap in size of the different groups. It is also possible that the enzyme 293 concentration is high and the kinetics of degradation is much faster than the increase in number of 294 additional crosslinks. It should be noted that the release of the 100 nm nanoparticles should follow the 295 degradation curve, since the theoretical pore size calculated [35] is smaller than the size of the 296 nanoparticles (10-20 nm) i.e., the nanoparticles can only be released as the microgels degrade, 297
Supplemental Table 3 . 
degradation. Trypsin-responsive microgels were exposed to 0.01 mg/mL trypsin and elastase-307 responsive were exposed to pooled CF patient-derived airway supernatant; scale bar = 10 µm. (B) 308
Mean ± SEM plots of the percent of non-degraded microgels remaining in the trap over 30 minutes for 309
PEG microgels (N = 5), trypsin-(N = 5) and elastase-(N = 3) responsive microgels. Trypsin-and 310
elastase-responsive microgels were tested for each 20 for the Nano-in-Microgels increased for all formulations; however, Nano-in-Microgels with a higher 337 polymer concentrations exhibited lower uptake by macrophages in vitro. This trend was observed for 338 both the trypsin-and elastase-responsive microgels, Figure 5B , and suggests that to avoid rapid 339 clearance by phagocytes a higher starting polymer concentration may potentially be helpful in vivo. FluoSpheres (Blue FS). These Nano-in-Micro formulations were instilled naïve Balb/c lungs which were 379 excised at 0.5, 6, and 24 hours, and the radiant efficiency of the whole lung was measured using IVIS. 380
Fluorescence intensity decreased with time but was still visible at 6 and 24 hours after injection 381 suggesting a slower clearance rate ( Figure 6A -B and Supplemental Figure 5A ). We expect that the 382 levels of proteases present in these naïve lungs were relatively low, and thus the measured decrease in 383 fluorescence should not be due to enzymatic degradation of the peptide backbone on the microgels, 384 which was confirmed by the similar rates of clearance for both the protease-and non-protease 385 degradable (PEG-PEG) Nano-in-Microgel formulations. 386 387 A secondary goal of these experiments was to ensure that nanoparticles are not being released in 388 normal, disease-free lungs -a key criterion to minimize side effects. To evaluate this we looked for the 389 presence of the 100 nm Blue FluoSphere (ex/em 350/440; DAPI equivalent) in various cell types in the 390 lungs of naïve mice following delivery using flow cytomtery. In the absence of significant proteolytic 391 degradation (in naïve animals we do not expect disease-related proteolytic enzymes to be present in 392 the lung), few Blue FluoSpheres should be released from the microgels (labeled with DyLight 650). This 393 was confirmed by flow cytometry showing that alveolar macrophages (Live CD45+Ly6G-394 SiglecF+CD11c+CD11b-) and neutrophils (Live CD45+Ly6G+) were not positive for free nanoparticles 395 (i.e. nanoparticles released out of microgels; 100 nm Blue FluoSphere+ and DyLight 650-), Figure 6C . 396
Additionally epithelial cells (Live CD45-EpCAM+) were also negative for free nanoparticles 397 (Supplemental Figure 5B) . Importantly this also showed little to no uptake by neutrophils and minimal 398 uptake of the Nano-in-Microgel by alveolar macrophages (lack of macrophages positive for DyLight 399 650) suggesting avoidance of rapid macrophage phagocytosis within the early timepoint. 
